S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY
Véronique Minard‐Colin(Inserm), Birgit Burkhardt(University Hospital Münster), Michelle L. Hermiston(VinUniversity), André Baruchel(Université Paris Cité), Samuel John(Southwestern Medical Center), Daisuke Tomizawa(National Center For Child Health and Development), Jochen Buechner(Oslo University Hospital), F. Locatelli(Bambino Gesù Children's Hospital), Shannon L. Maude(Children's Hospital of Philadelphia), Stacy Cooper(Sidney Kimmel Comprehensive Cancer Center), Tracey O’Brien(Sydney Children's Hospital), Aisha Masood(Novartis (United States)), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Joerg Krueger(Hospital for Sick Children), Marianne Ifversen(Copenhagen University Hospital), Santiago Redondo(Novartis (Spain)), Sara Ghorashian(Great Ormond Street Hospital), Kim Vettenranta(Universität Hamburg), Alan S. Wayne(University of Southern California), Andishe Attarbaschi(Cancer Research Institute of the Slovak Academy of Sciences), B. González Martínez(Hospital Universitario La Paz), Christine L. Phillips(Cincinnati Children's Hospital Medical Center), Britta Vormoor(Princess Máxima Center), R. Awasthi(Novartis (United States)), H. Hiramatsu(Kyoto University), Sara Napolitano(Azienda Ospedaliera San Gerardo), Seong Lin Khaw(Royal Children's Hospital), Simon Newsome(Novartis (United Kingdom))
Cited by 5
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867